Flerie completes merger with Biosergen

• Flerie completed its merger with Biosergen today, taking over all of Biosergen's assets and liabilities.
• Biosergen's operations moved to a new subsidiary of Flerie Invest.
• The merger consideration comprises 2,667,234 newly issued ordinary shares, bringing the total outstanding to 89,364,936 ordinary shares.
• Biosergen shareholders registered on October 26, 2026, will receive one newly issued ordinary share for every 31 shares held.
• Delivery of the merger consideration is expected on or about October 28, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Flerie AB published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.